Compare Incyte Corporation (INCY) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs MasTec Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while MasTec Inc trades at $343 (market cap $26.60B). The key difference: MasTec Inc is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals.
| INCY | MTZ | |
|---|---|---|
Market Cap | $23.11B | $26.60B |
Sector | Health | Technology |
52-Week High | $118.52 | $437.51 |
52-Week Low | $67.38 | $172.51 |
Enterprise Value | $19.13B | $29.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
MasTec (MTZ) trades at $336.61, up 2.13% with strong analyst support (88.9% buy ratings) and a consensus price target of $497.45. The stock shows a bearish technical signal despite recent earnings beats, with Q1 2026 EPS of $1.39 surpassing expectations. The company's $1.65 billion acquisition of Superior Group positions it to capitalize on AI-driven data center infrastructure demand, supported by a record $20.3 billion backlog. Valuation metrics include a P/E of 57.72 and ROE of 14.53%, indicating premium pricing but solid profitability.
Outlook remains positive due to infrastructure spending tailwinds and strategic acquisitions, though high valuation and integration risks from the Superior deal warrant caution. Revenue growth is projected to rise from $14.30 billion in 2025 to $15.30 billion in 2026, with net income margin improving to 2.94%. Key risks include execution challenges and macroeconomic sensitivity, but institutional bullishness suggests upside potential if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
